Abstract While the effects of TCR affinity and TGFb on CD8
Introduction

CD8
? T cells emerge from the thymus bearing T-cell receptors (TCRs) with a wide range of affinities. Key to the understanding of TCR affinity and T-cell function has been the development of altered peptide ligands (APLs). Studies using APLs demonstrate high-affinity interactions between the TCR and peptide-MHC class I complexes (pMHC) result in greater induction of CD8
? T-cell responses [1, 2] . However, the manner in which APLs with differential TCR affinity dictate susceptibility to TGFb-mediated suppression remains unknown.
Transforming growth factor beta (TGFb) is an immunoregulatory cytokine with activity affecting T-cell proliferation, differentiation, survival, and self-tolerance [3] [4] [5] [6] [7] . TGFb signals through a heterotetrameric complex of TGFb receptor (TGFbR)-I and TGFbRII, which phosphorylates the receptor-regulated Smad signaling proteins (R-Smads), including Smad2 and Smad3. These R-Smads then complex with the co-Smad, Smad4, which together translocate to the nucleus to activate transcription of certain TGFb-responsive genes [8, 9] . The inhibitory Smads, including Smad7, act by preventing phosphorylation of the R-Smads, while the noncanonical inhibitor of TGFb signaling, the regulator of G-protein signaling (RGS)-3, acts by forming complexes with the R-Smads and co-Smad and prevents the activation of TGFb-induced gene transcription [10] . Mice with T cells that lack the ability to respond to TGFb rapidly experience multiorgan, multitarget T-cellmediated autoimmunity without any prior modification of the T-cell repertoire [11] [12] [13] . Studies analyzing these mice have demonstrated that self-reactive T cells exist in the natural repertoire and that TGFb signaling is required to prevent these responses in the normal physiological state. Additional studies have shown that TGFb-insensitive polyclonal CD8
? T cells possess enhanced antitumor function and can prevent tumors from developing [14] . However, little is known about natural variations in CD8 ? T-cell sensitivity to TGFb signaling.
TCR affinity and TGFb-mediated suppression have been individually shown to regulate CD8
? T-cell responses. However, the interplay between these variables remains unknown. In this study, we now demonstrate that while decreased TCR ligand affinity initially results in weakened responses, such interactions prime the resultant effector cells to respond more strongly to cognate antigen upon secondary exposure. In spite of this, responses by CD8
? T cells primed with lower-affinity TCR ligands are more effectively suppressed by TGFb. These results highlight antigen affinity as an important concern in cancer immunotherapy that may not be addressed by vaccination or increasing the density of the presented antigen.
Materials and methods
Cells and mice
All cells were cultured in RPMI supplemented with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), 2 mM L-glutamine (Mediatech, Manassas, VA), and 1% penicillin/streptomycin (Mediatech, Manassas, VA), unless otherwise noted. Six-week-old, specific-pathogen-free C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I) mice were purchased from Jackson Laboratories. All mice were housed at The University of Chicago animal facility under conventional conditions, and animal experimentation was conducted in accordance with Institutional Animal Care and Use Committee (IACUC) guidelines.
Peptides
OVA 257 (SIINFEKL) and, in order of decreasing reported affinity for the OT-I TCR, the APLs Y3 (SIYNFEKL), Q4 (SIIQFEKL), T4 (SIITFEKL), and V4 (SIIVFEKL) were purchased from New England Peptide (Gardner, MA).
In vitro activation and restimulation
Irradiated feeder EL-4 cells were loaded for 2 h with OVA 257 peptide or OVA APL (1 lg/ml) and washed twice to remove unloaded peptide. OT-I splenocytes were co-cultured with feeder EL-4 cells for two days in media supplemented with 30 U/ml IL-2 (R&D Systems, Minneapolis, MN) prior to the addition of TGFb1 (EMD Chemicals, Inc., Gibbstown, NJ) at a final concentration of 20 ng/ml. Some cells were washed in PBS and stained for analysis of extracellular and intracellular markers before the addition of TGFb1. At day 5, cells were restimulated with OVA 257 peptide (100 ng/ml) overnight in the presence of GolgiPlug (BD Biosciences, San Diego, CA) and TGFb1 at a final concentration of 20 ng/ml as described. Cells were then washed in PBS and stained for surface and intracellular markers. To examine initial responses to the OVA APLs, OT-I splenocytes were cultured with various concentrations (ranging from 5 lM to 1 pM) of the peptide for a total of 8 h (6 h after the addition of GolgiPlug) without exogenous IL-2. Cells were washed in PBS and stained for analysis by flow cytometry.
Antibodies and flow cytometry
All mouse antibodies against cell surface and intracellular markers were purchased from Ebioscience (San Diego, CA), except APC-Cy7 anti-CD3 (BD Biosciences, San Diego, CA), Pacific Orange anti-CD8 (Invitrogen, Carlsbad, CA), PE anti-TGFbRII (R&D Systems, Minneapolis, MN), Pacific Blue anti-T-bet (BioLegend, San Diego, CA), FITC anti-KLRG1 (Southern Biotech, Birmingham, AL), anti-TGFbRI (Santa Cruz Biotechnology, Santa Cruz, CA), and anti-RGS3. The anti-RGS3 antibody has been described previously [15] . Extracellular and intracellular marker staining was performed as previously described [16] .
Statistical analyses
Sigmoidal dose-response and exponential association curves were fit to data using GraphPad Prism (GraphPad Software, San Diego, CA). For the sigmoidal dose-response curves, separate curves for each peptide were accepted only if the extra sum-of-squares F test yielded a P value of less than 0.05. The goodness of fit for the exponential association curves is indicated by R 2 value. To compare cytokine suppression across multiple experiments, one-way ANOVA with a Tukey HSD post-test was used to calculate P values. P values below 0.05 were deemed significant.
Results
Priming with low-affinity peptide ligands gives rise to effectors with enhanced function
In order to investigate the effect of TCR signaling strength at priming on effector function, OT-I CD8
? T cells were primed with EL4 cells loaded with wild-type (wt) OVA 257 or one of four single residue-substituted versions of the peptide, referred to collectively as APLs [1] . These APLs bear substitutions only at TCR-facing residues and not anchor residues and accordingly have been shown to affect OT-I TCR-binding affinity without affecting affinity of binding to the class I MHC molecule, H-2K b . Restimulation with 100 ng/ml wt OVA 257 was performed at day 5 after priming. While single cytokines are often used as measures of effector CD8
? T-cell function, a number of studies have shown that the simultaneous expression of several cytokines correlates far better with protective immunity than the magnitude of any one single cytokine [17] [18] [19] [20] . Therefore, antigen-specific production of the cytokines IFN-c, TNF-a and IL-2 were used as measures of effector function. In contrast to our expectations, a greater proportion of those cells primed with the lower-affinity APLs produced all three cytokines than those primed with higher-affinity ligands, including wt OVA 257 (Fig. 1a, b , Table 1 ). Previous studies have reported that decreased antigen density or availability can lead to enhanced responses at restimulation by maintaining increased levels of TCR and the coreceptor CD8 at the cell surface [21, 22] .
However, in response to decreased ligand affinity at the same concentration in our system, no differences were observed with respect to CD3e or CD8 expression at the cell surface (Supplemental Fig. 1) . Furthermore, the effect of lower-affinity ligands was not mediated by activating fewer cells during the 5-day priming period, as the expression of CD44 and CD62L in CD8
? T cells remain unchanged between stimulatory cultures regardless of ligand affinity (Supplemental Fig. 2 ).
Priming with low-affinity peptide ligands gives rise to effectors with increased susceptibility to TGFb signaling As peptide ligand affinity was found to control the quality and magnitude of the secondary response, we endeavored to also investigate the role of ligand affinity during priming on later sensitivity to immune regulation by TGFb. This was accomplished by priming the OT-I CD8
? T cells in the same manner as before but incubating half of the cells in media containing physiological concentrations (20 ng/ml) of TGFb1 [23] beginning at day 2 after priming and during restimulation at day 5. As the magnitude of the secondary Fig. 1 Priming with lower-affinity peptide ligands leads to enhanced secondary responses but also increased sensitivity to TGFb-mediated suppression. OT-I splenocytes were primed on peptide-loaded, irradiated EL4 cells for 5 days in vitro prior to restimulation with 100 ng/ml OVA 257 for all groups. Half of all samples were incubated in 20 ng/ml TGFb starting at day 2 and during restimulation. Cells were analyzed by flow cytometry for polycytokine production in the CD3 effector response was enhanced by lower-affinity ligands, we expected to find that these cells were also more resistant to TGFb-mediated immune regulation. However, while there was little apparent effect of TGFb on cells primed with higher-affinity ligands, there were large apparent suppressive effects on those primed with the lower-affinity ligands (Fig. 1a, b , Table 1 ). Furthermore, this effect was observed with respect to production of all three cytokines (Fig. 2a , Table 1 ).
Ligand affinity at priming correlates with susceptibility to suppression
To further gain insight into the functional effects of APLs with lower affinities, we stimulated naive OT-I CD8 ? T cells with various concentrations of OVA 257 or the APLs and measured cytokine output. As expected, higher concentrations of the lower-affinity APLs were necessary to reach half-maximal stimulation (EC 50 ) and the maximum proportion of cells producing cytokines with stimulation from lower-affinity ligands was also lower than those stimulated with higher-affinity ligands (Fig. 2b and Supplemental  Fig. 3 ). Plotting these experimentally determined relative EC 50 values, which are similar to previously published values for these peptides [1] , against the degree of suppression with each peptide ligand reveals a clear relationship between peptide ligand affinity during priming and later susceptibility to TGFb-mediated suppression during the effector phase (Fig. 2c) . The curves that best correlate with the data are defined by exponential association equations, suggesting that as the affinity of the TCR for the priming OT-I splenocytes were primed and restimulated as shown in Fig. 1 . The percentages of the resulting effector CD8
?
T cells producing a particular set of cytokines or all of those producing an individual cytokine (Cumulative) are shown. Data shown are representative of at least three individual experiments with similar results Fig. 2 Degree of TGFb-mediated suppression is dependent on the affinity of the ligand on which CD8 ? T cells are primed. a CD8 ? T cells were primed and restimulated as shown in Fig. 1 . Data shown are representative of at least three individual experiments with similar results c ligand decreases, the degree of suppression will eventually approach an asymptotic maximum. In addition, all of these equations include y-intercepts that fall near zero (some are negative), which corresponds to the suppressive effect of 20 ng/ml TGFb on cells originally primed with wt OVA 257 .
Hence, lower-affinity peptide priming leads to increased susceptibility to TGFb-mediated suppression. Statistically significant differences in the degree of TGFb-mediated suppression were evident with respect to each cytokine or concurrent production of all three cytokines (Fig. 2d) . To determine the molecular basis for the increased susceptibility to TGFb-mediated suppression, we similarly primed cells with wt OVA 257 and each of the APLs and analyzed expression levels of proteins in the TGFb signaling pathway, namely TGFbRI and RII. Yet for neither of these proteins did expression levels correlate with susceptibility to TGFb-mediated suppression. There were no significant changes in expression for TGFbRI, TGFbRII, or the inhibitory Smad7 (Fig. 3 and data not shown) . Interestingly, expression of RGS3, a recently defined noncanonical inhibitor of TGFb signaling [10] , was found to be higher in cells primed with lower-affinity peptide ligands (Fig. 3) . In order to more completely recreate the suppressive conditions and thus accurately recreate the susceptible phenotype, the original priming scheme was followed. However, at day 5 after priming, the cells were analyzed for expression levels of each of the TGFb pathway proteins. Once again, expression levels for the TGFb receptors I and II were stable across the different peptide ligands (Fig. 3) . However, while RGS3 once again was more highly expressed in cells that were primed with lower-affinity ligands in the absence of TGFb, the presence of TGFb reversed these phenotypes: RGS3 was upregulated in cells primed with high-affinity ligands and downregulated in cells primed with low-affinity ligands (Fig. 3) . Thus, in the suppressive environment, cells primed with lower-affinity ligands adopted a more TGFb-responsive phenotype. Interestingly, this change was not accompanied by any significant changes in activation status markers, such as CD44, CD62L, KLRG1, CD127, T-bet, or Eomes (Supplemental Fig. 2 ). In addition, no changes were observed with respect to CD3, CD44, CD62L, RGS3, TGFbRI, TGFbRII, KLRG1, CD127, or T-bet between priming cultures at day two, prior to the addition of TGFb (Supplemental Fig. 4) .
Discussion
While previous studies have defined the role of TCR affinity in central tolerance, our study highlights the potential interplay between TCR affinity and TGFb in peripheral tolerance. The outcome of low-affinity TCR ligand stimulation on CD8
? T-cell cytokine production during the primary response is known; however, the effects of such priming on secondary activation and effector function have not yet been defined. Through the use of OVA 257 peptide and residue-substituted peptide OVA 257 analogs for which the OT-I TCR has reduced affinity, we have shown that OT-I CD8
? T cells primed with loweraffinity ligands are better suited to respond to the cognate antigen upon restimulation. Furthermore, while it has been reported that functional avidity may be modulated by antigen dose through mechanisms involving altering surface expression levels of the TCR and the CD8 coreceptor [21, 22] , we find that the levels of CD3e and CD8 are unchanged at the surface regardless of the affinity of the priming ligand. This effect may partially underlie the importance of low-affinity self-reactivity in the periphery, where CD8
? T cells may be better suited to recognize foreign, high-affinity antigens and thus resolve infection because of earlier recognition of self-peptide ligands.
One of the central issues in immunology is the way in which autoimmunity is prevented or controlled. This is especially significant for T-cell-mediated autoimmunity, as T cells are positively selected on the basis of self-antigen recognition during thymic development yet are not generally self-reactive in the periphery. The prevailing explanation for this phenomenon is that because T cells that emerge from thymic development have only a low-affinity interaction with self-antigen due to negative selection, such an interaction could not normally lead to a productive immune response [24, 25] . Our results demonstrate an additional mechanism to avert autoimmunity, whereby CD8
? T cells that have been primed with such a lowaffinity interaction become more sensitive to regulation by TGFb while those primed with high-affinity interactions are minimally affected. This mechanism allows the host to selectively suppress those CD8
? T-cell clones that may be deleterious while maintaining those that, by virtue of TCR affinity for pMHC, may be considered strictly foreign antigen-specific, even while both are responding to the same antigen in the same microenvironment. The same principle can be applied to tumor-reactive CD8
? T cells, as they generally recognize tumor-associated antigens (most of which are unaltered self-proteins) with very low affinity. This mechanism to avoid autoimmunity would then allow the tumor to more effectively suppress CD8 ? T-cell-mediated immune responses, particularly against the tumor itself, via TGFb.
The immune system has evolved the capacity to mount responses to foreign pathogens while avoiding responses to self-antigens. From studies showing that loss of TGFb signaling in T cells leads rapidly to multitarget autoimmunity, it can be inferred that self-reactive conventional T cells exist in the natural repertoire and are kept in check through normal levels of TGFb [11, 12] . In addition, as mice reconstituted with TGFb-insensitive CD8
? T cells prevent EL4 thymoma or B16 melanoma tumors from developing without any therapeutic intervention, these tumors appear to require the suppressive function of TGFb to evade immune destruction [14, 26] . However, very little is known about differences in TGFb sensitivity in T-cell populations. Sanjabi et al. have shown that during the contraction phase, short-lived effector cells respond to TGFb by undergoing apoptosis, whereas memory progenitor effector cells are preferentially maintained despite elevated TGFb levels [27] . There is evidence that both antigen affinity and availability during priming control the size of the resulting memory population [1, 28, 29] . It can be hypothesized that in our model, those CD8
? T cells primed with high-affinity ligands are more predisposed to becoming memory cells than those primed with lowaffinity ligands.
A noncanonical function of RGS3 in regulating TGFb signaling has recently been defined [10] . RGS3 has been shown to bind Smad2, Smad3, and Smad4, thereby impeding heteromerization of R-Smads and Smad4 and preventing TGFb-induced, Smad-mediated transcriptional activation [10] . While no differences were observed with respect to expression levels of the type I or II TGFb receptors or the inhibitory Smad, Smad 7, RGS3 expression correlated with sensitivity to TGFb-mediated suppression of effector function in the presence of TGFb1. Previous studies have shown that RGS protein expression may be modulated by TLR signaling in DCs [30] and as a result of activation in B cells [31] . However, our data represent the first evidence that RGS3 expression can be modulated in response to both TGFb signaling and a program resulting from TCR affinity during priming.
Our data demonstrate that while lower TCR ligand affinity results in less intense initial responses, such interactions during priming lead effector cells to become better able to respond to the cognate antigen upon secondary antigen exposure. Despite this, these cells are also more effectively suppressed by TGFb. Collectively, these results suggest a novel tolerance mechanism, whereby CD8
? T cells are discriminately regulated by TGFb according to the affinity of the ligand on which they were initially primed. Furthermore, these findings suggest that the low-affinity TCR ligands expressed by tumors may render responding CD8 ? T cells more sensitive to TGFb-mediated suppression and that this programming may be avoided by initially priming CD8
? T cells with higher-affinity ligands.
